Show simple item record

dc.contributor.authorSelfe, J
dc.contributor.authorShipley, JM
dc.date.accessioned2020-06-03T11:51:28Z
dc.date.issued2019-07-01
dc.identifier.citationAndrology, 2019, 7 (4), pp. 536 - 544
dc.identifier.issn2047-2919
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/3690
dc.identifier.eissn2047-2927
dc.identifier.doi10.1111/andr.12658
dc.description.abstractThe insulin-like growth factor (IGF) axis plays key roles in normal tissue growth and development as well as in the progression of several tumour types and their subsequent growth and progression to a metastatic phenotype. This review explores the role of IGF system in normal germ cell development and function in addition to examining the evidence for deregulation of IGF signalling in cancer, with particular relevance to evidence supporting a role in testicular germ cell tumours (TGCTs). Despite the clear preclinical rationale for targeting the IGF axis in cancer, there has been a lack of progress in identifying which patients may benefit from such therapy. Future employment of agents targeting the IGF pathway is expected to concentrate on their use in combination with other treatments to prevent resistance and exploit their potential as chemo- and radiosensitizers.
dc.formatPrint-Electronic
dc.format.extent536 - 544
dc.languageeng
dc.language.isoeng
dc.publisherWILEY
dc.rights.urihttps://creativecommons.org/licenses/by/4.0
dc.subjectGerm Cells
dc.subjectAnimals
dc.subjectHumans
dc.subjectNeoplasms, Germ Cell and Embryonal
dc.subjectTesticular Neoplasms
dc.subjectReceptor, IGF Type 1
dc.subjectSomatomedins
dc.subjectDrug Resistance, Neoplasm
dc.subjectMolecular Targeted Therapy
dc.subjectCarcinogenesis
dc.titleIGF signalling in germ cells and testicular germ cell tumours: roles and therapeutic approaches.
dc.typeJournal Article
dcterms.dateAccepted2019-05-05
rioxxterms.versionofrecord10.1111/andr.12658
rioxxterms.licenseref.urihttps://creativecommons.org/licenses/by/4.0
rioxxterms.licenseref.startdate2019-07
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfAndrology
pubs.issue4
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Sarcoma Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Molecular Pathology
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Sarcoma Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Molecular Pathology/Sarcoma Molecular Pathology
pubs.publication-statusPublished
pubs.volume7
pubs.embargo.termsNot known
icr.researchteamSarcoma Molecular Pathology
dc.contributor.icrauthorSelfe, Joanna
dc.contributor.icrauthorShipley, Janet


Files in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record

https://creativecommons.org/licenses/by/4.0
Except where otherwise noted, this item's license is described as https://creativecommons.org/licenses/by/4.0